JP Morgan Chase
RXDX

JP Morgan Chase’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

JP Morgan Chase’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-250,000
Closed -$26.8M – 7495
2023
Q1 		$26.8M Buy
250,000
+46,600
+23% +$5.36M ﹤0.01% 1458
2022
Q4 		$22.4M Buy
+203,400
New +$13.2M ﹤0.01% 1588

Other funds holding RXDX

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
FCA
FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

JP Morgan Chase's RXDX Position: Q2 2023 in Review

JP Morgan Chase sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 101,586 shares — an estimated $10.9M sold.

JP Morgan Chase first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $14M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

  • JP Morgan Chase reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • JP Morgan Chase sold 101,586 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $10.9M.
  • JP Morgan Chase first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
  • JP Morgan Chase's Prometheus Biosciences, Inc. Common Stock position peaked at $14M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.